PTI / Peptide Therapy Index
Clinical and preclinical peptide therapy research — indexed by study type, assessed for evidence quality. Independent. No affiliates.
In GLORY-1, mazdutide 6 mg produced mean body-weight change of approximately negative 15 percent versus negative 0.5 percent with placebo at 48 weeks. The placebo-subtracted treatment difference was approximately negative 14 percentage points. Orforglipron 36 mg achieved approximately negative 12 percent at 72 weeks in ATTAIN-1 but no head-to-head RCT between the two agents exists.
Yes. The EECOH-2 phase 3 trial demonstrated that once-weekly ecnoglutide at both tested doses was non-inferior to dulaglutide in HbA1c reduction over 52 weeks, with the higher dose achieving superiority. The gastrointestinal adverse-event profile was mild-to-moderate and did not exceed dulaglutide rates.
The Phase 3 LUCIDITY trial (NCT06747468), with topline data announced August 18, 2026, showed that avexitide — a first-in-class GLP-1 receptor antagonist — reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo (p=0.000003) over 16 weeks in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Amylyx plans an NDA by end of 2026.
The 2026 Mateescu Pharmaceutics review (doi:10.3390/pharmaceutics18050625) identifies a fundamental asymmetry in BPC-157's route-of-administration evidence: oral delivery has the strongest mechanistic rationale for gastrointestinal indications because luminal — not systemic — exposure is the therapeutic target, while parenteral routes face a sub-16-minute intravenous half-life and species-variable intramuscular bioavailability (14–51%) that undermine systemic exposure modelling.
The July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, KPV, and TB-500 for the 503A Bulks List, and 7-5 for MOTS-c — overriding staff's negative briefing documents. The vote is non-binding; formal rulemaking must follow. Retatrutide was not evaluated under this framework: it is advancing toward a 2027 BLA filing on Phase 3 RCT data.
As of mid-2026, no completed randomized controlled trial has evaluated BPC-157 in any acute human muscle injury indication. The musculoskeletal efficacy record is entirely preclinical. One Phase 2 RCT — NCT07437547, targeting acute grade II hamstring strain — is recruiting, with co-primary endpoints of MRI-assessed injury volume at Day 14 and time to return to unrestricted sport.
The Peptide Therapy Index catalogues primary-source research on peptide therapies — clinical trials, preclinical studies, and evidence reviews — assessed for study type and quality. Every entry identifies whether the underlying evidence is from randomised controlled trials, animal models, case series, or review syntheses.
No commercial affiliations. No advertising. No supplements sold. Editorial standards →